Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • PARP inhibitors have opened the era of targeted therapy in ovarian cancer; • Major therapeutic improvements have been limited to the high grade serous subtype; • The panorama of possible clinically actionable targets in ovarian cancer is wider. • New druggable alterations and matched drugs are under investigation.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
